



(51) International Patent Classification:

A61K 31/519 (2006.01) A61P 35/00 (2006.01)
A61K 31/475 (2006.01) A61P 25/00 (2006.01)

(21) International Application Number:

PCT/US2015/039677

(22) International Filing Date:

9 July 2015 (09.07.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/024,284 14 July 2014 (14.07.2014) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333
Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors: **BLOMGREN, Peter, A.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).
CLARKE, Astrid; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **CURRIE, Kevin, S.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **DI PAOLO, Julie**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **KROPP, Jeffrey, E.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **LEE, Seung, H.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster


City, CA 94404 (US). **LO, Jennifer, R.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **MITCHELL, Scott, A.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **SCHMITT, Aaron, C.**; 32 Linden Avenue, Hamden, CT 06518 (US). **SWAMINATHAN, Sundaramoorthi**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **XIONG, Jin-Ming**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **XU, Ji-anjun**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **ZHAO, Zhongdong**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(74) Agents: **REMY, Brian** et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: SYK INHIBITORS



Formula I

(57) Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R^1 , R^2 , R^3 , and R^4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. In certain embodiments, also disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof.



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*